New drug shows promise in reducing kidney disease inflammation
NCT ID NCT06362759
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This study tested a drug called TOUR006 in 143 adults with chronic kidney disease and high levels of inflammation (measured by hs-CRP). The goal was to see if monthly or quarterly injections could safely lower inflammation. The study compared the drug to a placebo and focused on reducing hs-CRP levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site - 0101
Birmingham, Alabama, 35209, United States
-
Site - 0102
Fort Mill, South Carolina, 29707, United States
-
Site - 0103
Greenville, South Carolina, 29607, United States
-
Site - 0104
Phoenix, Arizona, 85018, United States
-
Site - 0105
Houston, Texas, 77043, United States
-
Site - 0106
Chicago, Illinois, 60655, United States
-
Site - 0107
San Antonio, Texas, 78212, United States
-
Site - 0108
Knoxville, Tennessee, 37923, United States
-
Site - 0109
Manassas, Virginia, 20110, United States
-
Site - 0110
Charlotte, North Carolina, 28208, United States
-
Site - 0111
Lampasas, Texas, 76550, United States
-
Site - 0112
Valencia, California, 91355, United States
-
Site - 0113
Greenacres City, Florida, 334667, United States
-
Site - 0114
Council Bluffs, Iowa, 51501, United States
-
Site - 0115
Morton, Illinois, 61550, United States
-
Site - 0117
Fargo, North Dakota, 58104, United States
-
Site - 0119
Port Orange, Florida, 32127, United States
-
Site - 0120
Cincinnati, Ohio, 45219, United States
-
Site - 0122
Savannah, Georgia, 31406, United States
-
Site - 0123
Las Vegas, Nevada, 89121, United States
-
Site - 0125
San Dimas, California, 91773, United States
-
Site - 0126
Providence, Rhode Island, 02818, United States
-
Site - 0127
Marion, Ohio, 43302, United States
-
Site - 0128
Valencia, California, 91355, United States
-
Site - 0129
Metairie, Louisiana, 70006, United States
-
Site - 0130
Middletown, New York, 10940, United States
-
Site - 0132
Bethlehem, Pennsylvania, 18017, United States
-
Site - 0134
Kenosha, Wisconsin, 53144, United States
-
Site - 0135
Huntsville, Alabama, 35763, United States
-
Site - 0136
Stamford, Connecticut, 06905, United States
-
Site - 0141
San Antonio, Texas, 78255, United States
-
Site - 0144
Plantation, Florida, 33317, United States
-
Site - 0145
Huntsville, Alabama, 35805, United States
-
Site - 0147
Morgantown, West Virginia, 26505, United States
-
Site - 0148
Greenville, Texas, 75402, United States
-
Site - 0149
Pembroke Pines, Florida, 33024, United States
-
Site - 0150
McKinney, Texas, 75069, United States
-
Site - 0151
Tampa, Florida, 33634, United States
Conditions
Explore the condition pages connected to this study.